Presentations on recent advances in the treatment of neuroendocrine tumors (NETs) and new findings from the NETTER-1 clinical study on PRRT with Lutathera along with posters on a wide variety of subjects about NETs will be part of the program during the 2016 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), to be held in San Francisco, California from January 21-23. The theme of the symposium is Insight on Novel Mechanisms and Precision Care.
The “Recent Advances in the Treatment of Neuroendocrine Tumors” breakout session will be presented on January 22.
- Pamela L. Kunz, MD
Stanford University School of Medicine
New Options for Neuroendocrine Tumors: Results of Recent Trials
- Lisa Bodei, MD, PhD
European Institute of Oncology
Rationale for Peptide Receptor Radiation Therapy
- Dik J. Kwekkeboom, MD, PhD
Erasmus University Medical Center
The Rotterdam Experience: Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
Advanced Accelerator Applications has announced that carcinoid/NET specialist Dr. Jonathan R. Strosberg will present new safety and efficacy data from the pivotal NETTER-1 Phase 3 clinical study. The January 22 presentation is NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. This communication has also been selected for ASCO GI’s official Press Program and the new key findings of the NETTER-1 study will be presented to journalists in a presscast on Tuesday, January 19, 2016.
The Phase 3 NETTER-1 trial, an international, randomized clinical study, compared treatment using Lutathera with a double dose of Octreotide LAR in patients with inoperable midgut NETs under Octreotide LAR treatment and overexpressing somatostatin receptors. The primary endpoint was the assessment of progression-free survival.
According to Dr. Strosberg, “The findings were, in my opinion, extraordinarily impressive, the median progression-free survival improved by nearly 80%, which is fairly unprecedented in oncologic studies. The finding is important because limited therapeutic options exist for such patients, who comprise 20% to 45% of neuroendocrine tumor cases.”
Over 20 posters will focus on neuroendocrine tumors including:
• Angiogenic gene expression in primary neuroendocrine tumors and their metastases
• Significance of lymph node metastasis in pancreatic neuroendocrine tumors
• Recurrence rates of resected appendix carcinoid tumors: A 20-year experience at Memorial Sloan Kettering Cancer Center
• Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up
• Does receptor status impact survival of patients with mid-gut neuroendocrine tumors?
• Blood neuroendocrine tumor gene cluster analysis to predict somatostatin analog response
• Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial
• Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
• Retrospective phase II study of efficacy and safety of 177Lu-DOTATOC peptide receptor radiotherapy in patients with advanced neuroendocrine tumours
• Carcinoid syndrome-related symptoms in pancreatic neuroendocrine tumors (pNETs) and impact on health care utilization